Search

everythinglearnresearchcommunity

for

Search:↓

Mutant keratins cause inflammation in Epidermolysis Bullosa Simplex, suggesting targeting them could help treat the disorder.

Black hairy tongue can be an early sign of graft-versus-host disease after stem cell transplants.

CD8+ T cells play a key role in graft-versus-host disease in certain mice models.

People with allergies or high eosinophil levels have a higher chance of severe hair loss from alopecia areata, and sudden hair loss can indicate chronic graft-versus-host disease.

Topical spironolactone may help treat ocular graft-versus-host disease with minimal side effects.

Permanent hair loss after a stem cell transplant can be a sign of chronic immune system attack on the scalp.

Chronic graft-versus-host disease in the skin shows strong Th1 immune response and unique barrier issues.

High amphiregulin in the skin is a bad sign for acute graft-versus-host disease.

Exosome-enriched vesicles from placental cells improved skin condition in a patient with chronic graft-versus-host disease.

Injecting recipient splenocytes into donors' thymus can prevent graft-versus-host disease.

PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.

Gingerol may help treat chronic graft-versus-host disease by improving immune cell balance.

Patients with graft-versus-host disease often have nail changes related to the nail matrix, with severity not linked to skin condition.

Rapamycin increased survival in mice with severe chronic graft-versus-host disease by expanding regulatory T cells.

Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.

Mice with human fetal thymic tissue and stem cells developed symptoms similar to chronic graft-versus-host disease.

Patients with chronic graft-versus-host disease often have skin problems like vitiligo and alopecia areata.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Non-myeloablative stem cell transplants are a promising, less toxic option for older or weaker patients, with fewer side effects and good outcomes.

Some children who had stem cell transplants developed permanent hair loss, especially when treated with a drug called busulphan.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

Patients often experience long-lasting changes to their hair after stem cell transplants.

Adjusting the medication tacrolimus resolved a boy's red nail beds after a stem cell transplant.

Umbilical cord blood transplantation improved the boy's symptoms despite complications.

Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.

Permanent hair loss after bone marrow transplant can be caused by chemotherapy or chronic graft-versus-host disease.

Skin changes like hair loss, white patches, and nail changes are common in children after bone marrow transplants, often linked to chronic rejection.

A man developed autoimmune issues after a transplant, improved with treatment, but died from leukemia relapse.

Topical treatments and skin care improve transplant-related atopic dermatitis in children.

A Japanese bone marrow transplant patient developed a rare skin cancer possibly linked to long-term use of the medication voriconazole.